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Suspensions of oxygen-filled bubbles are under active investigation as potential
means of relieving tissue hypoxia. Intravenous administration of large quantities
of bubbles is, however, undesirable. Previous work by the authors has demon-
strated that tumor oxygen levels can be increased following oral administration of
phospholipid stabilized oxygen nanobubbles. The aim of this study was to deter-
mine whether this would enhance the efficacy of sonodynamic therapy (SDT),
which is known to be inhibited in hypoxic tissue. Experiments were conducted
in amurinemodel of pancreatic cancer. Animals were treated with SDT (intratu-
moural injection of 1mMRose Bengal followed by exposure to 1MHzultrasound,
0.1 kHz pulse repetition frequency, 30% duty cycle, 3.5 W cm−2 for 3.5 minutes)
either with or without a prior gavage of oxygen bubbles. A statistically signifi-
cant reduction in the rate of tumor growth was observed in the groups receiving
oxygen nanobubbles either 5 or 20 minutes before SDT. Separate measurements
of tumor oxygen using a fiber optic probe and expression of hypoxia inducible
factor (HIF)1α following tumor excision, confirmed the change in tumor oxygen
levels. These findings offer a potentially promising new approach to relieving
tissue hypoxia in order to facilitate cancer therapy.
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1 INTRODUCTION
Hypoxia, that is, an imbalance between oxygen supply
and consumption, is a common feature of solid tumors.
Its primary cause is the disorganized microarchitecture of
vascular networks in cancerous tissues which results in
impaired blood flow and inadequate oxygen delivery to
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
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cells.[1] Hypoxia can be further exacerbated by disease- or
treatment-associated anemia.[2] Tumor hypoxia is associ-
ated with impaired therapeutic response, malignant pro-
gression and poor clinical outcomes.[3,4] In particular it
has been shown to lower the efficacy of treatments depen-
dent on reactive oxygen species (ROS) generation, such
as chemo-, radio- and photodynamic therapy.[5,6] This is
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likely due in part to the fact that a low oxygen concen-
tration inhibits efficient ROS generation. Hypoxia is also
believed to play a role in the development of aggressive cell
phenotypes which have suppressed apoptosis pathways,
greatermetastatic potential and aremore resistant to thera-
peutic interventions.[7] In addition, impaired vasculariza-
tion, which is the major cause of low oxygen content in
tumors, also prevents therapeutic agents, such as drugs or
sensitizers, from efficiently diffusing into cancerous cells
that are too remote from blood vessels.[8]
It is important to state that the role of ROS in cancer
progression, although undoubtedly significant, is complex
and not yet fully understood.[9] ROS have been associated
with increased cell proliferation and survival, while at the
same time they are also capable of inducing cell death
pathways.[10] This notwithstanding, multiple clinical and
pre-clinical studies have shown that alleviating hypoxia
can improve the efficacy of ROS-dependent therapies.[11]
Multiple methods have been explored and can be roughly
classified as: (i) manipulating breathing gas composition;
(ii) manipulating circulatory system structure and compo-
nents; (iii) changing oxygen consumption of cells; and (iv)
introducing exogenous oxygen carriers. It should be noted
that there has also been extensive research into developing
bioreductive drugs and sensitizers for hypoxic tissue, but
these are not directly relevant to the present study.
Arguably the most obvious solution for alleviating
hypoxia is increasing oxygen concentration in the breath-
ing gas of the patient. Hyperbaric oxygen (HBO) therapy
is a well-established procedure, involving breathing 100%
oxygen under increased pressure, and has been widely
used for treatment of conditions such as decompression
sickness and carbon monoxide poisoning. It has also
shown promise in cancer treatment when used in combi-
nation with radio-, chemo- and photodynamic therapy.[12]
A number of studies, however, have reported no benefit;[13]
and the risk of systemic oxygen toxicity, as well as tech-
nical difficulties and safety concerns associated with com-
bining hyperbaric oxygen chambers with other therapies,
have prevented its widespread use in oncology.
Another breathing gas that has been used for tumor oxy-
genation is carbogen—a mixture of carbon dioxide and
oxygen. The carbon dioxide content in carbogen is usually
5% but can be as low as 1.5% or as high as 50% in different
compositions. Its action is based on increasing blood levels
of carbon dioxide, which triggers mechanisms associated
with suffocation, such as deeper breathing and increase in
heart rate, and lead to better blood oxygenation. However,
similar to HBO, its therapeutic efficacy has not been con-
clusively demonstrated.[14]
A different approach to increasing local oxygen lev-
els is manipulating the circulatory system or its compo-
nents. Methods of enhancing oxygen transport include
stimulation of red blood cell production by erythropoi-
etin treatment[15] and introducing hemoglobin oxygen
release co-factors, for example 2,3-diphosphoglycerate.[16]
Conversely, some researchers have attempted to mediate
tumor oxygen levels by introducing drugs that inhibit oxy-
gen consumption,[17] glucose (making use of the Crabtree
effect),[18] or by simple mechanisms such as manipulating
local tumor temperature.[19] Unfortunately, while enhanc-
ing the existing mechanisms in the body to fight hypoxia
is an elegant concept, a major problem of such methods
is insufficient selectivity that can lead to serious systemic
side effects.
The fourth category is the use of exogenous oxygen
sources or carriers. Tumor hypoxia is often partly caused
by disease- or treatment-related anemia, which limits the
oxygen-carrying capabilities of blood and can thus be
directly addressed by additional carriers. Themost obvious
choice of carrier is a red blood cell. As mentioned above,
however, attempts to stimulate red blood cell production
in patients often results in unwanted systemic side effects.
Similarly, the use of blood transfusions in this context car-
ries several risks, for example, transfer of infection, and has
not been shown to give a sufficient advantage in cancer
therapy.[20] Alternative strategies have been put forward
for in situ oxygen production using nanoparticles,[21,22] or
oxygen-generating implants.[23] The major limitation of
artificial oxygen generation in the body, however, is the
need for extremely careful regulation and localization.
Artificial blood products have been widely explored
as a means of exploiting the efficiency of hemoglobin
as an oxygen carrier, without the risk of eliciting an
immune response. However, clinical trials of these blood
substitutes, though promising, have largely failed because
their complication rates were still higher than those
of traditional blood transfusions. Research in this area
continues[24] to date but remains problematic.[25] Another
important class of oxygen transporters that has been
investigated is perfluorocarbon-based (PFC-based) agents.
PFCs have low solubility and diffusivity in water, and
therefore form relatively stable particles, and offer the
possibility of high oxygen loading. Unlike hemoglobin,
they have a linear oxygen release response as a function
of surrounding oxygen concentration. They are, however,
non-reactive, stable and biologically neutral; and a further
advantage for cancer therapy is the possibility to use them
in combination with focused ultrasound (US) as cavitation
nuclei to enhance extravasation of therapeutics. To this
end, low molecular weight PFCs (perfluoropropane and
perfluorobutane) have been used to form microbubbles
that can be loaded with oxygen for localized delivery
under ultrasound exposure. Several groups have shown
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that oxygen loaded microbubbles are capable of reducing
hypoxia in vitro and in vivo.[26–30] McEwan et al.[27] have
shown enhanced response to ultrasound-responsive drugs
(sonodynamic therapy) in vivo in pancreatic tumors, and
Eisenbrey et al.[29] have successfully increased breast
tumor oxygenation levels in vitro by 20 mmHg. Encour-
agingly, no adverse side effects were observed in these
studies. There have also been multiple studies of smaller
diameter oxygen loaded bubbles for enhancing various
cancer therapies in recent years.[31,32]
PFC based carriers for oxygen delivery have, however,
suffered from the same problems as hemoglobin-based
agents, that is, unwanted side effects at high intravenous
concentrations;[33] and the stability of pure oxygen bub-
bles is low due to its high diffusivity.[26] Consequently both
intraperitoneal and oral administration of oxygen-loaded
bubbles have also been investigated.[34,35] Oral adminis-
tration in particular offers significant advantages, as it
reduces the risk of infection, improves patient acceptabil-
ity and compliance and reduces cost. Importantly, it also
reduces the risks of embolism and/or lipid toxicity asso-
ciated with intravenous injection of bubbles that severely
limit the quantities that can be administered. For exam-
ple, the maximum injectable dose of microbubble con-
trast agent for a human is < 5 mL. Previous work by
the authors demonstrated that an orally delivered suspen-
sion of oxygen nanobubbles could produce an increase
in tumor oxygen levels comparable to that generated
by intravenously injected microbubbles.[35] A subsequent
study reported similar findings and a direct anti-tumor
effect of the nanobubbles themselves in a breast cancer
model.[36] The aim of the present study was to determine
whether this approach could be used to improve thera-
peutic response to sonodynamic therapy, by exploiting the
temporary increase in tumor oxygen levels to facilitate pro-
duction of ROS and hence achieve a localized cytotoxic
effect.
2 RESULTS
2.1 Bubble size distribution and
concentration
The size distribution and concentration of the nanobub-
bles were measured before and after sparging with either
oxygen or nitrogen gas to investigate any changes in the
population. The size distribution was not found to be
significantly different between the three conditions (Fig-
ure 1A). A small increase in concentration was observed
following sparging, presumably due to the additional agi-
tation of the liquid during this process.
F IGURE 1 A, Size distributions and (B) concentrations of the
nanobubble suspensions after production (air) and after sparging
with nitrogen or oxygen measured using the nanoparticle tracking
analyzer (NanosightNS300). (n = 3; error bars indicate standard
deviation)
2.2 Bubble oxygen content
The measurements of oxygen release after introducing
oxygenated nanobubbles into deoxygenated (nitrogen-
saturated) medium were consistent with those reported
by Owen et al.[35] showing a rapid elevation in oxy-
gen concentration upon injection of either oxygenated
nanobubbles or oxygenated milliQ water (control), with
the bubble suspension producing amore sustained change
(Figure 2).
2.3 Response to sonodynamic therapy
Mice bearing human pancreatic BxPC-3 xenograft tumors
were dosed with oxygen bubbles via gavage followed by an
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F IGURE 2 Measurements of oxygen concentration after
addition of 1 mL of oxygenated sample (nanobubble solution or
Milli-Q R© water) to 10 mL of deoxygenated (nitrogen-saturated)
water under constant mixing of solution and nitrogen flow in vial
headspace (n = 3; measurement every 10 seconds; error bars
indicate standard deviation)
intratumoural injection of a sonosensitizer (Rose Bengal)
and exposure to ultrasound either 5 or 20minutes post gav-
age. Control groups receiving no treatment, oxygen bub-
bles only or Rose Bengal and ultrasound only were also
included. A statistically significant difference in the rate
of change tumor volume was observed between the groups
receiving SDT only and those receiving both SDT and oxy-
gen bubbles 19 days after treatment (Figure 3). There was
no statistically significant difference between the results
for those animals receiving the bubbles 5 minutes before
treatment and those receiving them 20 minutes before.
The bubbles alone had no significant effect upon tumor
growth (please see the supporting information for individ-
ual tumor volume curves and final weight).
F IGURE 4 Expression of HIF-1α at a transcriptional level in
tumours extracted from mice 30 minutes after administration of
oxygen bubbles via gavage (n = 5; *P < 0.05 determined via one
tailed t-test; error bars indicate standard error)
2.4 HIF-1α expression
HIF1-α was selected as a physiological probe for oxy-
gen delivery as its rapid degradation in the presence
of oxygen provides a direct and immediate indicator of
increased tumor oxygen levels. Consistent with previous
experiments,[35] a statistically significant reduction in the
expression of HIF-1α was measured in excised tumors
from mice receiving oxygen bubbles as compared to those
receiving the control (unsparged) gavage (Figure 4).
2.5 Intratumoural oxygen
measurements
Also consistent with previous experiments[35] mea-
surements from an implanted oxygen probe (Figure 5)
F IGURE 3 Effect of oral administration of oxygen bubbles upon tumour response to sonodynamic therapy. Treated animals received
oxygen bubbles by gavage and/or SDT, that is, an intratumoural injection of Rose Bengal followed by exposure to ultrasound for 3.5 minutes.
SDT was administered either 5 or 20 minutes after the oxygen bubble gavage. Animals were treated on Days 0, 5, 11 and 15. (n = 5, * P < 0.05,
** P < 0.01; determined via a one-tailed t-test for measurements at day 19; error bars indicate standard error)
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F IGURE 5 Partial pressure of oxygen in a mouse xenograft
tumour model for human pancreatic cancer following
administration of bubbles sparged with oxygen (n = 5) or air (n = 5)
or no treatment (n = 3). No statistically significant differences were
observed between oxygen and air bubble groups. Error bars indicate
standard deviation
indicated an increase in partial pressure within the tumor
following administration of oxygen bubbles (prior to
ultrasound exposure). The variance in the measurements
was however very large, such that there was no statistically
significant difference between the effect of the oxygenated
and air sparged bubbles. This was attributed to the fact
that, under the terms of the animal license, measurements
had to be conducted with a single probe, the position of
which could not be varied.
3 DISCUSSION
3.1 Orally administered nanobubbles
promote SDT
The data shown in Figure 3 support the hypothesis that the
increase in tumor oxygenation produced by oral admin-
istration of oxygen bubbles has the potential to enhance
tumor response to SDT. This finding is also consistent
with the results of previous studies using intravenously
delivered oxygen microbubbles to promote SDT, in which
similar changes in tumor oxygen levels and in hypoxia
inducible factor expression to those in Figures 4 and 5
were measured and found to correlate with therapeutic
effect;[27,37] and of intravenous nanobubbles to promote
photodynamic therapy.[31] No indicators of acute toxicity
were observed and there were no statistically significant
changes in animal bodyweight over the course of the study
(Figure S7). This is very encouraging for the potential use
of oxygen bubbles as a therapeutic adjuvant as it indicates
that the current limitations imposed onmaximum injected
volume may be overcome by changing the administration
route. The simplicity of the approach moreover makes it
suitable for use with other therapies for which relieving
hypoxia is known to be beneficial such as radiotherapy or
immunotherapy.
3.2 The timing of treatment
administration did not affect the
therapeutic outcome
There was no statistically significant difference between
the treatment groups receiving SDT 5 or 20 minutes after
oxygen bubble administration. The results shown in Fig-
ure 5 suggest that thismay be because the treatment should
have been delivered at a later point once the oxygen level
in the tumor had risen to its maximum level. Unfortu-
nately due to the restrictions of the license underwhich the
experiments were performed, it was not possible to simul-
taneouslymeasure tumor oxygen and deliver SDT. Further
work is needed to make a detailed study of the circulation
kinetics of the bubbles, to optimize the treatment protocol
and also to assess the effect of multiple treatments which
have been shown to enhance the therapeutic effect in the
case of SDT with microbubbles.[38]
3.3 Further work is needed to elucidate
the mechanism of oxygen delivery
An interesting question for future investigation is the
mechanism of oxygen delivery. The quantity of encap-
sulated oxygen can be estimated from both the oxygen
concentration and bubble size and concentration mea-
surements. The former indicate that the quantity of oxygen
in the undiluted suspension is of the order of 10 mg L−1
of oxygen. From Figure 1, the total volume of oxygen that
could be encapsulated within bubbles of the size indicated
in Figure 1 is approximately 10−8 m3 mL−1 of suspension.
Assuming that there is a sufficiently tightly packed coating
on the bubble surface to balance surface tension, this also
corresponds to ∼10 mg L−1 of oxygen. A 0.2 mL dose
of oxygen bubble suspension thus contains ∼0.002 mg
oxygen. Even assuming 100% of the ingested bubbles were
transferred to the bloodstream, this quantity of oxygen
would be unlikely to produce either a large or sustained
effect, being approximately equivalent to the quantity
inhaled in 1 breath.[39] This quantity is also inconsistent
with the measured changes in tumor oxygen in Figure 5
or reported in[35] that persist over tens of minutes.
A possible explanation for this discrepancy, is that
the lipid coated bubbles, being of comparable size to
chylomicrons,[40] are passing into the bloodstream via the
digestive tract and acting as oxygen carriers. The duration
of the change in tumor oxygen levels suggests the bubbles
are circulating and thus can potentially absorb oxygen
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during their passage through the lung capillary bed and
subsequently release it in areas of hypoxia. This is one
of the mechanisms by which suspensions of perfluoro-
carbon nanodroplets are assumed to function as blood
substitutes;[41,42] and indeed lecithin micelles have also
been investigated in this context on account of the high
solubility of oxygen in lecithin and their negligible toxicity.
The timescale over which the increase in tumor partial
pressure was observed would be consistent with upper
gastrointestinal tract absorption.[43] If this hypothesis is
correct then the bubble suspension would be increasing
the oxygen carrying capacity of the blood by 0.05-0.5 mg
L−1 depending on the proportion of bubbles passing into
the blood stream (for comparison a 5% increase in hema-
tocrit would provide 1.4 mg L−1). Over tens of minutes
the corresponding increase in the oxygen concentration
gradient in the tumor could deliver much more significant
quantities of oxygen than that initially encapsulated in the
administered dose. This could potentially explain why the
air bubbles in this study and the argon sparged bubbles in
the previous study (Figure 4B in reference[35]) were also
found to increase tumor oxygen levels and influence HIF-
1α when they were not expected to. Further investigation
is however needed both to confirm this hypothesis and
then understand the rates of gas transfer and why the oxy-
genated bubbles still produced a more significant effect.
4 CONCLUSIONS
The results of this study showed that an improved response
to SDT was observed following oral administration of oxy-
gen nanobubbles in a mouse model of pancreatic cancer.
This finding is consistent with previous observations of
increased tumor oxygenation produced by orally delivered
oxygen bubbles. The duration over which tumor oxygen
levels were elevated and calculation of the quantities of
encapsulated oxygen suggest that the primary effect of the
bubbles may be to increase the oxygen carrying capacity of
the blood.Amore detailed investigation of the effect of oxy-
gen bubbles upon the spatial distribution of tumor hypoxia
and the relationship to perfusion and other tissue charac-
teristics is needed to fully assess their potential as a thera-
peutic adjuvant.
5 EXPERIMENTAL SECTION
5.1 Materials and suppliers
Lecithin and citric acid were purchased from Special
Ingredients (Chesterfield, Derbyshire, UK). Rose Bengal
(RB), phosphate buffered saline (PBS), cell culture media,
glycyrrhizic acid and glycerol were purchased from
Sigma-Aldrich Ltd (Gillingham, Dorset, UK). Oxygen
and nitrogen cylinders were purchased from BOC gases
(Guildford, Surrey, UK). Hypnorm and Hypnovel were
purchased from VetaPharma Ltd. (Leeds, West Yorkshire,
UK) and Roche (Welwyn Garden City, Hertfordshire,
UK) respectively. Matrigel was purchased from BD Bio-
sciences (Erembodegem, Belgium). Anagel ultrasound
couplant was purchased from Ana Wiz Ltd. (Surrey,
UK). Singlet Oxygen Sensor Green was purchased from
Thermo Fisher Scientific (Loughborough, UK). Cells
were purchased from ATTC, LGC Standards (Teddington,
Surrey, UK). Independent identification was not carried
out. Animals were purchased from Envigo (Huntingdon,
Cambridgeshire, UK) for the sonodynamic therapy exper-
iments and Charles River (Portishead, Avon, UK) for the
oxygen probe experiments described below.
5.2 Bubble fabrication
The bubble solutions were prepared according to Owen
et al.[35] Briefly, filtered, de-ionized water was mixed with
glycyrrhizic acid (3 mg mL−1), lecithin (3 mg mL−1), citric
acid (5 mg mL−1) and glycerol (0.0125 mL mL−1). The
solution was then stirred for 30 mins on a hot plate at
50oC. For individual experiments, 5 mL of the solution was
then transferred to a glass vial and sparged with oxygen,
nitrogen, or air as required for 3 minutes. The vial was
then immediately sealed and mechanically agitated for
30 seconds.
5.3 Bubble characterization
The size distributions and concentrations of the bub-
ble suspensions were measured at different stages of
preparation using a nanoparticle tracking analyzer (NTA)
(Nanosight NS300, Malvern, PA). The solution was diluted
1:10,000with filtered deionizedwater.Measurementswere
made before sparging, then after sparging with N2 or O2 to
examine any changes in the size distribution.
The oxygen content of the bubble suspensions was mea-
sured using an optical oxygen sensor (OXYMINIMinisen-
sor Oxygen Meter, PreSens Precision Sensing GmbH,
Regensburg, Germany) with temperature compensation.
An SP-PSt3-NAU oxygen sensor was attached to the inner
surface of a glass vial on the level approximately corre-
sponding to the middle of the solution. The oxygen sen-
sor temperature probe and a magnetic bar were placed
inside; the vial was placed on amixing plate (500 rpm), put
into a fume hood and covered to protect it from strong air
flow. 10 mL of milliQ water were added into the vial and
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nitrogen gas at 1 bar was bubbled through the liquid until
the oxygen sensor showed a negligible oxygen concentra-
tion. 5 mL of sample (bubbles or Milli-Q R© water for con-
trol) were sparged with oxygen for 3 mins, and then 1 mL
of oxygenated solution was added into the measuring vial.
The nitrogen feed was taken out of the solution but kept
near the surface of the liquid to maintain the gas concen-
tration gradient. All oxygenmeasurements were calibrated
and carried out at room temperature
5.4 In vivo experiments
All animal procedures were carried out in accordance with
the UK Animals (Scientific Procedures) Act 1986 and with
local ethical committee approval. Animals were housed in
individually ventilated cageswith amaximumof 6 animals
per cage, a 12 hour light/dark cycle, unrestricted access to
food and water, and environmental enrichment.
5.5 Sonodynamic therapy
BxPc-3 human pancreatic tumor cells (1 × 106, 1:1
media:Matrigel) were subcutaneously implanted into the
dorsumof C.B-17/IcrHanHsd-Prkdc scidmice using isoflu-
rane anesthesia. Mice were both male and female and a
minimum of 6 weeks old when implanted. They were ran-
domly allocated to groups 4–5 weeks after cell implanta-
tion when the tumors had reached an average volume of
150 mm3 (Day 0). A minimum of 5 mice was included
in each group. Mice were anaesthetized with a mixture
of Hypnorm and Hypnovel, diluted in an equal volume
of water for injection [1:1:2 ratio]. This was administered
as a single 100 µL intraperitoneal injection. For those
mice receiving Rose Bengal, 100 µL of a 1 mM solution
was injected intratumorally. Mice receiving the oxygen
nanobubble suspension were given 100 µL using a flexible
gavage. Immediately prior to dosing with the oxygenated
bubbles, the vial was shaken vigorously for approximately
1 minute. Those mice receiving both Rose Bengal and oxy-
gen nanobubbles, were given the latter 30 minutes after
the RB injection while they were still anaesthetized. Ultra-
sound was applied to the tumor using a Sonidel SP100
probe (Sonidel Ltd., Republic of Ireland) for 3.5 minutes at
an intensity of 3.5 W cm−2, center frequency 1 MHz, pulse
repetition frequency 0.1 kHz and 30% duty cycle). Ultra-
sound gel was applied to the probe head to ensure good
coupling and the probe was slowly moved over the entire
tumor during the treatment. US treatmentwas given either
5 minutes or 20 minutes after the oxygen nanobubble gav-
age. Animals were treated on Day 0, 5, 11 and 15 according
to a previously optimized protocol. Tumorsweremeasured
a minimum of 5 times per week using calipers, tumor vol-
ume = (width x length x height)/2.
5.6 Tumor oxygen measurements
In a separate experiment, BxPc-3 xenografts were again
established by subcutaneous injection of tumor cells
(1 × 107, 1:1 media:Matrigel) in the right flank of athymic
nude female mice (8 weeks old) under isoflurane anes-
thesia. When the tumors reached an average volume of
150 mm3, animals were randomly assigned to one of three
groups, receiving no treatment (n = 3), air sparged bub-
bles (n = 5) or oxygen sparged bubbles (n = 5). In these
experiments animals were gavaged with 0.4 mL suspen-
sion, anaesthetized using isoflurane in air and placed on
a heat mat to maintain core body temperature. An oxy-
gen/temperature bare-fiber sensor of tip diameter 350 µm
(Oxylite by Oxford Optronix) was inserted into the cen-
ter of the tumor, and tumor oxygen partial pressure (in
mmHg) was recorded every 5 minutes for 1 hour.
5.7 Hypoxia Inducible Factor (HIF)-1α
expression
Following the oxygen measurements described above,
the animals were euthanized. The tumors were harvested
by surgical excision and RNA extracted using Trizol
(Invitrogen, Paisley, UK) and reverse transcribed using a
first strand cDNA synthesis kit according to the manu-
facturer’s instructions (Roche, Welwyn Garden City, UK).
Real Time Quantitative PCR (RT-Q-PCR) was undertaken
using SYBR green (Fermentas, Cambridge, UK) and gene-
specific primers in a Lightcycler 480 (Roche, Welwyn
Garden City, UK). Using Hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) as a reference, expression of
HIF-1α was calculated using the comparative CT (ΔΔCT)
method.
Supporting Information is available from the Wiley
Online Library or from the author.
ACKNOWLEDGEMENTS
The authors thank Cancer Research UK and the Engineer-
ing and Physical Sciences Research Council for supporting
thiswork through aPioneer award and grants EP/I021795/1
and EP/L024012/1 respectively. John Callan thanks Nor-
brook Laboratories Ltd. for an endowed chair. EB and AV
thank the Clarendon Foundation for Post Graduate Schol-
arships. AV also thanks Exeter College for a Santander
scholarship.
CONFL ICTS OF INTEREST
Joshua Owen and Eleanor Stride are co-inventors
on a patent (Stride, E., Averre, R., Owen, J. (2015)
8 OWEN et al.
Nanoencapsulated Oxygen. UK Patent Application No.
1512728.5), which has been filed in relation to one of the
formulations described in the paper. Avrox Technologies
Ltd. has licensed this patent but did not fund this work
or play any role in the study design, data collection
and analysis, decision to publish, or preparation of the
manuscript.
DATA AVAILAB IL ITY STATEMENT
The data that supports the findings of this study are avail-




1. D. W. Siemann, Cancer Treat. Rev. 2011, 37, 63.
2. P. Vaupel, Oncologist 2004, 9, 4.
3. M. S. Nakazawa, B. Keith, M. C. Simon, Nat. Rev. Cancer 2016,
16, 663.
4. P. Vaupel, A. Mayer, Cancer Metastasis Rev. 2007, 26, 225.
5. L. B. Harrison, Oncologist 2002, 7, 492.
6. M. Rebucci, C. Michiels, Biochem. Pharmacol. 2013, 85, 1219.
7. P. Vaupel, Oncologist 2008, 13, 21.
8. A. S. Narang, S. Varia, Adv. Drug Deliv. Rev. 2011, 63, 640.
9. P. T. Schumacker, Cancer Cell 2006, 10, 175.
10. P. Storz, Front. Biosci. 2005, 10, 1881.
11. M. Yu, M. Dai, Q. Liu, R. Xiu, Cancer Treat. Rev. 2007, 33, 757.
12. N. S. Al-Waili, G. J. Butler, J. Beale, M. S. Abdullah, R. W. B.
Hamilton, B. Y. Lee, P. Lucus, M. W. Allen, R. L. Petrillo, Z. Car-
rey, M. Finkelstein, Adv. Ther. 2005, 22, 659.
13. M. Nordsmark, M. Overgaard, J. Overgaard, Radiother. Oncol.
1996, https://doi.org/10.1016/S0167-8140(96)91811-3.
14. L. Martin, E. Lartigau, P.Weeger, P. Lambin, A.M. Le Ridant, A.
Lusinchi, P. Wibault, F. Eschwege, B. Luboinski, M. Guichard,
Radiother. Oncol. 1993, 27, 123.
15. G. Stüben, C. Pöttgen, K. Knühmann, K. Schmidt, M. Stuschke,
O. Thews, P. Vaupel, Int. J. Radiat. Oncol. Biol. Phys. 2003, 55,
1358.
16. A. M. Shannon, D. J. Bouchier-Hayes, C. M. Condron, D.
Toomey, Cancer Treat. Rev. 2003, 29, 297.
17. N. Crokart, B. F. Jordan, C. Baudelet, G. O. Cron, J. Hotton, K.
Radermacher, V. Grégoire, N. Beghein, P. Martinive, C. Bouzin,
O. Feron, B. Gallez, Clin. Cancer Res. 2007, 13, 630.
18. S. A. Snyder, J. L. Lanzen, R. D. Braun, G. Rosner, T. W. Secomb,
J. Biaglow, D. M. Brizel, M. W. Dewhirst, Int. J. Radiat. Oncol.
Biol. Phys. 2001, 51, 494.
19. C. W. Song, H. J. Park, C. K. Lee, R. Griffin, in Int. J. Hyperth.,
2005, pp. 761–767.
20. J. Varlotto, M. A. Stevenson, Int. J. Radiat. Oncol. Biol. Phys.
2005, 63, 25.
21. J. Kim, H. R. Cho, H. Jeon, D. Kim, C. Song, N. Lee, S. H. Choi,
T. Hyeon, J. Am. Chem. Soc. 2017, 139, 10992.
22. W. Zhu, Z. Dong, T. Fu, J. Liu, Q. Chen, Y. Li, R. Zhu, L. Xu, Z.
Liu, Adv. Funct. Mater. 2016, 26, 5490.
23. C.-C. Huang, W.-T. Chia, M.-F. Chung, K.-J. Lin, C.-W. Hsiao, C.
Jin, W.-H. Lim, C.-C. Chen, H.-W. Sung, J. Am. Chem. Soc. 2016,
138, 5222.
24. R. Haruki, T. Kimura, H. Iwasaki, K. Yamada, I. Kamiyama,
M. Kohno, K. Taguchi, S. Nagao, T. Maruyama, M. Otagiri, T.
Komatsu, Sci. Rep. 2015, 5, 12778.
25. A. I. Alayash, Trends Biotechnol. 2014, 32, 177.
26. J. J. Kwan, M. Kaya, M. A. Borden, P. A. Dayton, Theranostics
2012, 2, 1174.
27. C. McEwan, J. Owen, E. Stride, C. Fowley, H. Nesbitt, D.
Cochrane, C. C. Coussios, M. Borden, N. Nomikou, A. P.
McHale, J. F. Callan, J. Control. Release 2015, 203, 51.
28. L. Liu, S. Chang, J. Sun, S. Zhu, M. Yin, Y. Zhu, Z. Wang, R. X.
Xu, Cancer Lett. 2015, 361, 147.
29. J. R. Eisenbrey, L. Albala, M. R. Kramer, N. Daroshefski, D.
Brown, J. Bin Liu, M. Stanczak, P. O’Kane, F. Forsberg, M. A.
Wheatley, Int. J. Pharm. 2015, 478, 361.
30. S. Chang, T. Si, S. Zhang, M. A. Merrick, D. E. Cohn, R. X. Xu,
Ultrason. Sonochem. 2016, 28, 31.
31. R. Song, D. Hu, H. Y. Chung, Z. Sheng, S. Yao, ACS Appl. Mater.
Interfaces 2018, 10, 36805.
32. M. S. Khan, J. Hwang, K. Lee, Y. Choi, Y. Seo, H. Jeon, J. W.
Hong, J. Choi, Cancers (Basel). 2019, 11, https://doi.org/10.3390/
cancers11101464.
33. H. Horinouchi, H. Yamamoto, T. Komatsu, Y. Huang, E.
Tsuchida, K. Kobayashi, Cancer Sci. 2008, 99, 1274.
34. J. A. Feshitan, N. D. Legband, M. A. Borden, B. S. Terry, Bioma-
terials 2014, 35, 2600.
35. J. Owen, C. McEwan, H. Nesbitt, P. Bovornchutichai, R. Averre,
M. Borden, A. P. McHale, J. F. Callan, E. Stride, PLoS One 2016,
11, https://doi.org/10.1371/journal.pone.0168088.
36. A. Mahjour, M. Khazaei, E. Nourmohammadi, H. Khoshdel-
Sarkarizi, A. Ebrahimzadeh-Bideskan, H. R. Rahimi, A.
Safipour Afshar, J. Cell. Biochem. 2019, 120, 15546.
37. C. McEwan, S. Kamila, J. Owen, H. Nesbitt, B. Callan, M. Bor-
den, N. Nomikou, R. A. Hamoudi, M. A. Taylor, E. Stride, A. P.
McHale, J. F. Callan, Biomaterials 2016, 80, 20.
38. H. Nesbitt, Y. Sheng, S. Kamila, K. Logan, K. Thomas, B. Callan,
M.A. Taylor,M. Love, D.O’Rourke, P. Kelly, E. Beguin, E. Stride,
A. P. McHale, J. F. Callan, J. Control. Release 2018, 279, 8.
39. H. B. Davis, J. E. van Dyke, J. Biol. Chem. 1933, 100, 455.
40. P. Tso, J. A. Balint, Am. J. Physiol. Liver Physiol. 2017, 250, G715.
41. D. R. Spahn, Crit. Care 1999, 3, R93.
42. J. G. Riess, Artif. Cells. Blood Substit. Immobil. Biotechnol. 2005,
https://doi.org/10.1081/BIO-200046659.
43. R. Schwarz, A. Kaspar, J. Seelig, B. Künnecke. Magn Resonan
Med. 2002, 48, 255.
SUPPORT ING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
How to cite this article: J. Owen, K. Logan, H.
Nesbitt, S. Able, A. Vasilyeva, E. Bluemke, V.
Kersemans, S. Smart, K. A. Vallis, A. P. McHale, J.
F. Callan, E. Stride, Nano Select 2021, 1.
https://doi.org/10.1002/nano.202100038
